ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/12/21

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this event. For further details see: Alexion Pharmaceuticals (ALXN) Presents At J.P.Morgan Healthcare Conference - Slideshow

Alexion Pharmaceuticals ([[ALXN]] -0.2%) expects to exceed the high end of the company’s 2020 revenue guidance of $5.9B-5.95B that was previously provided by the company in connection with its Q3 financial results.Continued advancement of pipeline, including initiation of three Ph...

- Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 - - Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 billion - - Recently announced acqu...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

2020 represented a year full of turmoil and despair for some and opportunity for others. There were 154 deals worth over $605 billion announced in 2020. The most interesting aspect of the year was how wide the spreads were in March 2020. For further details see: U.S. Mer...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 th at 7:30 a.m. ET. Audio webcasts of the presentations will be available live at: http://ir.alexion.co...

The world is awash with liquidity as interest rates remain at historic lows. Cheap liquidity is the fuel that will spark the next buyout bing in smaller cap biotech. A diversified ETF specializing in smaller cap biotechs is the perfect vehicle to capitalize on the trend as detaile...

WeissLaw LLP Reminds MTSC, EIDX, IPHI, and ALXN Shareholders About Its Ongoing Investigations PR Newswire NEW YORK , Dec. 30, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our inves...

Thanks to the COVID-19 pandemic, 2020 has been a great year for growth stocks, whereas value stocks have struggled to bounce back since the March market correction. However, the emergence of effective coronavirus vaccines last month has triggered a big shift by investors out of pricey growth ...

Aravive is drugging the GAS6-AXL pathway to develop new medicines across several cancer indications. Early clinical data has established safety for the company's lead drug candidate, AVB-500, and early efficacy signals in platinum-resistance ovarian cancer. AVB-500 has the potenti...